Polymyxins

Drug Overview

In the high-stakes environment of Infectious Disease and critical care, clinicians are increasingly confronted with “superbugs”—bacteria that have evolved to resist almost all modern antibiotics. When frontline and secondary treatments fail, the Polymyxins serve as an essential, life-saving intervention.

Represented prominently by Colistin (administered as the prodrug Colistimethate Sodium, or CMS), this archaic but highly potent antibiotic is universally designated as a “last resort” therapy. It is specifically reserved for severe, multi-drug resistant (MDR) Gram-negative infections. Because of its narrow therapeutic index and profound risk of causing Acute Tubular Necrosis (ATN), its administration requires meticulous dosing, rigorous monitoring, and deep pharmacological expertise.

• Generic Name: Colistimethate Sodium (CMS) / Colistin
• US Brand Names: Coly-Mycin M
• Route of Administration: Intravenous (IV) infusion, Intramuscular (IM – rarely used), Inhalation (off-label but standard for cystic fibrosis).
• FDA Approval Status: Fully FDA-approved for the treatment of acute or chronic infections due to sensitive strains of certain Gram-negative bacilli, particularly Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae.

What Is It and How Does It Work? (Mechanism of Action)

Colistin is a decades-old, naturally occurring polypeptide antibiotic produced by the bacterium Paenibacillus polymyxa. It functions as a highly specific, bactericidal Targeted Therapy directed at the outer membrane of Gram-negative bacteria.

Gram-negative bacteria are uniquely protected by an outer membrane composed largely of lipopolysaccharides (LPS). Colistin is a cationic (positively charged), amphipathic molecule that acts essentially as a molecular detergent.

1. Electrostatic Binding: The positively charged polymyxin molecule is strongly attracted to the negatively charged phosphate groups of lipid A, the core component of the bacterial LPS.
2. Ion Displacement: Upon binding, Colistin competitively displaces divalent cations (specifically calcium and magnesium . These ions normally function as the “molecular glue” that stabilizes the LPS layer.
3. Membrane Disruption: With the stabilizing ions removed, the hydrophobic tail of the Colistin molecule inserts itself into the bacterial outer membrane. This disrupts the crystalline arrangement of the lipid bilayer, causing massive physical derangement.
4. Cellular Lysis: The localized disruption expands, increasing the permeability of the bacterial envelope. This leads to the fatal leakage of intracellular contents and immediate bacterial cell death.

FDA-Approved Clinical Indications

Primary Indication

• “Last resort” for multi-drug resistant infections: Indicated for critical, life-threatening infections caused by carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), and multi-drug resistant Pseudomonas aeruginosa (CRPA). Its use is heavily weighed against the high risk of Acute Tubular Necrosis (ATN).

Other Approved Uses

• Ventilator-Associated Pneumonia (VAP) and Hospital-Acquired Pneumonia (HAP): Driven by susceptible Gram-negative MDR pathogens.
• Complicated Urinary Tract Infections (cUTI): When resistant pathogens are present and alternative therapies are exhausted.
• Cystic Fibrosis Exacerbations (Off-Label / Accepted Medical Use): Frequently administered via nebulized inhalation to treat chronic Pseudomonas colonization in the lungs, minimizing systemic nephrotoxicity.

Dosage and Administration Protocols

Crucial Clinical Note: Colistin dosing is notoriously complex and prone to medical errors. In the US, doses are prescribed based on Colistin Base Activity (CBA), whereas in Europe, doses are often prescribed in International Units (IU) of the prodrug CMS. 1 mg of CBA roughly equals 30,000 IU of CMS.

Dose Adjustments for Renal/Hepatic Insufficiency

• Renal Impairment: Because CMS is primarily cleared by the kidneys, profound dose adjustments are strictly mandatory. If the estimated Glomerular Filtration Rate (eGFR) falls, the drug will rapidly accumulate, accelerating Acute Tubular Necrosis (ATN).
  • Moderate Impairment (CrCl 30-50 mL/min): The daily dose is typically reduced to 2.5 to 3.8 mg/kg/day CBA, given in 2 divided doses.
  • Severe Impairment (CrCl < 10 mL/min): The dose is drastically reduced to 1.5 mg/kg/day CBA, given every 36 hours.
• Hemodialysis: CMS and active Colistin are partially cleared by hemodialysis. Supplemental dosing is required following a dialysis session.
• Hepatic Impairment: No specific dose adjustments are required for isolated hepatic dysfunction.

Clinical Efficacy and Research Results

According to the latest IDSA and ESCMID guidelines (2020-2026 updates) on the treatment of antimicrobial-resistant Gram-negative infections, Colistin has been largely relegated to a secondary “last-line” option behind newer beta-lactam and beta-lactamase inhibitor combinations (like ceftazidime-avibactam), strictly due to its toxicity profile.

• Survival Rates in MDR Infections: In cohorts with severe CRE or CRAB bacteremia where no other active agents are available, Colistin-based regimens achieve clinical cure rates of approximately 50% to 60%. However, underlying mortality in these critically ill populations remains high (30% to 50%).
• Synergistic Combination Therapy: Recent (2023-2025) clinical trials emphasize using Colistin as part of a combination regimen (e.g., combining it with meropenem or tigecycline) to exploit synergistic bacterial killing and potentially utilize lower doses to spare the kidneys.
• Nephrotoxicity Biomarkers: Contemporary data indicates that ATN occurs in 30% to 60% of patients receiving IV Colistin for more than 48-72 hours, marked by a rapid rise in serum creatinine and blood urea nitrogen (BUN).

Safety Profile and Side Effects

BLACK BOX WARNING: NEPHROTOXICITY AND NEUROTOXICITY

Colistimethate sodium can cause dose-dependent, severe nephrotoxicity (Acute Tubular Necrosis) and neurotoxicity. Concomitant use with other nephrotoxic or neurotoxic drugs (e.g., aminoglycosides, neuromuscular blocking agents) must be avoided. Respiratory arrest has been reported following intramuscular administration or impaired renal excretion.

Common Side Effects (>10%)

• Acute Tubular Necrosis (ATN): The direct toxic effect of the drug on the proximal renal tubules, leading to a profound drop in kidney filtration. (Management: Daily monitoring of serum creatinine, aggressive IV hydration if appropriate, and immediate dose adjustment).
• Paresthesia: Numbness, tingling, or a “crawling” sensation, particularly around the mouth and extremities.
• Dizziness and Vertigo: Due to central nervous system penetration.

Serious Adverse Events

• Neuromuscular Blockade leading to Respiratory Arrest: Colistin can block the release of acetylcholine at the neuromuscular junction, leading to profound muscle weakness and failure of the diaphragm. (Management: Immediate discontinuation, mechanical ventilatory support. Calcium chloride IV may be administered to attempt to reverse the blockade).
• Irreversible Kidney Failure: Severe ATN can progress to End-Stage Renal Disease requiring permanent hemodialysis.

Connection to Stem Cell and Regenerative Medicine / Research Areas

While Colistin is an archaic antimicrobial, its severe impact on the renal microenvironment makes it a focal point in regenerative nephrology research. Acute Tubular Necrosis (ATN) caused by Colistin physically destroys the epithelial lining of the renal tubules.

Current pre-clinical research explores the use of Biologic interventions and Mesenchymal Stem Cells (MSCs) to repair this specific iatrogenic damage. By understanding how Colistin induces oxidative stress and apoptosis in the proximal tubules, scientists are attempting to develop cellular therapies that can be administered concurrently or post-treatment to regenerate the tubular epithelium. Furthermore, researchers are actively developing liposomal or nanoparticle delivery systems as a Targeted Therapy to deliver Colistin directly to the bacterial site of infection while shielding the vulnerable renal microenvironment, theoretically allowing safe eradication of MDR infections without compromising future kidney viability.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Comprehensive Metabolic Panel (CMP): Accurate baseline serum creatinine and BUN are absolutely mandatory to dictate the initial starting dose.
• Neurological Baseline: A basic neuro-exam to assess baseline reflexes, muscle strength, and respiratory effort.
• Microbiology: Cultures and rigorous susceptibility testing (MIC determination) must confirm that the bacteria are resistant to safer alternatives before initiating Colistin.

Precautions during treatment

• Strict Fluid Monitoring: Strict tracking of input and output (urine volume) is vital. A sudden drop in urine output is often the first clinical sign of impending ATN.
• Avoidance of Co-Toxins: Concomitant use of nephrotoxins (e.g., IV contrast dye, NSAIDs, Vancomycin, Aminoglycosides) must be strictly avoided unless medically unavoidable.

Do’s and Don’ts

• DO ensure that your medical team is drawing your blood daily to check your kidney function (creatinine levels).
• DO report any numbness or tingling around your mouth, fingers, or toes immediately, as this is an early sign of neurotoxicity.
• DO alert your nurse immediately if you feel sudden muscle weakness or difficulty breathing.
• DON’T take any over-the-counter pain medications like Ibuprofen or Naproxen, as they will exponentially increase the damage to your kidneys.
• DON’T be alarmed if your doctors change the dose of this medication daily; dosing is highly fluid and adjusts directly to how your kidneys are performing that specific day.

Legal Disclaimer

The content provided in this guide is for informational and educational purposes only and is not intended to serve as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, infectious disease specialist, nephrologist, pharmacist, or other qualified healthcare provider with any questions you may have regarding a medical condition, prescribed medications, or treatment protocols. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.